The immunoproteasome: An emerging therapeutic target

Current Topics in Medicinal Chemistry

Volumn 11, Issue 23, 2011, Pages 2923-2930

  Lee, Wooin ^a   Kim, Kyung Bo ^a  

^a University of Kentucky   (United States)

Author keywords

Cancer; Degenerative disease; Immunoproteasome; Inhibitor; Protein degradation

Indexed keywords

BORTEZOMIB; CARFILZOMIB; GAMMA INTERFERON; IMMUNOPROTEASOME; IPSI 001; ONX 0912; PEPTIDE ALDEHYDE INHIBITOR; PR 957; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; TUMOR NECROSIS FACTOR ALPHA; UK 101; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; COLITIS; COLON CANCER; COLON INJURY; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG TARGETING; ENTERITIS; FIBROSARCOMA; HEMATOPOIETIC CELL; HUMAN; HUNTINGTON CHOREA; IMMUNOPHARMACOLOGY; INFECTION; INFLAMMATORY DISEASE; LUNG CANCER; MULTIPLE MYELOMA; MYCOSIS; NEOPLASM; NONHUMAN; PARASITOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION;

EID: 83455237998     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798281348     Document Type: Article

References (94)

1. Petroski, M. D. The ubiquitin system, disease, and drug discovery. BMC Biochem., 2008, 9 (Suppl 1), S7.
2. Marques, A. J.; Palanimurugan, R.; Matias, A. C.; Ramos, P. C.; Dohmen, R. J. Catalytic mechanism and assembly of the proteasome. Chem. Rev., 2009, 109, 1509-1536.
3. Konstantinova, I. M.; Tsimokha, A. S.; Mittenberg, A. G. Role of proteasomes in cellular regulation. Int. Rev. Cell. Mol. Biol., 2008, 267, 59-124.
4. Paul, S. Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Bioessays, 2008, 30, 1172-1184.
5. Cavaletti, G.; Jakubowiak, A. J. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk. Lymphoma, 2010, 51, 1178-1187.
6. Ri, M.; Iida, S.; Nakashima, T.; Miyazaki, H.; Mori, F.; Ito, A.; Inagaki, A.; Kusumoto, S.; Ishida, T.; Komatsu, H.; Shiotsu, Y.; Ueda, R. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia, 2010, 24, 1506-1512.
7. Gutman, D.; Morales, A. A.; Boise, L. H. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. Leukemia, 2009, 23, 2181-2183.
8. Testa, U. Proteasome inhibitors in cancer therapy. Curr. Drug Targets, 2009, 10, 968-981.
9. Richardson, P. G.; Xie, W.; Mitsiades, C.; Chanan-Khan, A. A.; Lonial, S.; Hassoun, H.; Avigan, D. E.; Oaklander, A. L.; Kuter, D. J.; Wen, P. Y.; Kesari, S.; Briemberg, H. R.; Schlossman, R. L.; Munshi, N. C.; Heffner, L. T.; Doss, D.; Esseltine, D. L.; Weller, E.; Anderson, K. C.; Amato, A. A. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol., 2009, 27, 3518-3525.
10. Papandreou, C. N.; Daliani, D. D.; Nix, D.; Yang, H.; Madden, T.; Wang, X.; Pien, C. S.; Millikan, R. E.; Tu, S. M.; Pagliaro, L.; Kim, J.; Adams, J.; Elliott, P.; Esseltine, D.; Petrusich, A.; Dieringer, P.; Perez, C.; Logothetis, C. J. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol., 2004, 22, 2108-2121.
11. Kuhn, D. J.; Hunsucker, S. A.; Chen, Q.; Voorhees, P. M.; Orlowski, M.; Orlowski, R. Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood, 2009, 113, 4667-4676.
12. Ho, Y. K.; Bargagna-Mohan, P.; Wehenkel, M.; Mohan, R.; Kim, K. B. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem. Biol., 2007, 14, 419-430.
13. Shenk, K. D.; Parlati, F.; Zhou, H. J.; Sylvain, C.; Smyth, M. S.; Bennett, M. K.; Laidig, G. J.: Compounds for enzyme inhibition. U. S. Patent 7,691,852, April 6, 2010.
14. Muchamuel, T.; Basler, M.; Aujay, M. A.; Suzuki, E.; Kalim, K. W.; Lauer, C.; Sylvain, C.; Ring, E. R.; Shields, J.; Jiang, J.; Shwonek, P.; Parlati, F.; Demo, S. D.; Bennett, M. K.; Kirk, C. J.; Groettrup, M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med., 2009, 15, 781-787.
15. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem., 1998, 67, 425-479.
16. Deshaies, R. J. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell. Dev. Biol., 1999, 15, 435-467.
17. Koegl, M.; Hoppe, T.; Schlenker, S.; Ulrich, H. D.; Mayer, T. U.; Jentsch, S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell, 1999, 96, 635-644.
18. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D.; Huber, R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature, 1997, 386, 463-471.
19. Kloetzel, P. M. Antigen processing by the proteasome. Nat. Rev. Mol. Cell. Biol., 2001, 2, 179-187.
20. Ortiz-Navarrete, V.; Seelig, A.; Gernold, M.; Frentzel, S.; Kloetzel, P. M.; Hammerling, G. J. Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature, 1991, 353, 662-664.
21. Aki, M.; Shimbara, N.; Takashina, M.; Akiyama, K.; Kagawa, S.; Tamura, T.; Tanahashi, N.; Yoshimura, T.; Tanaka, K.; Ichihara, A. Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J. Biochem. (Tokyo), 1994, 115, 257-269.
22. Groettrup, M.; Khan, S.; Schwarz, K.; Schmidtke, G. Interferongamma inducible exchanges of 20S proteasome active site subunits: why? Biochimie, 2001, 83, 367-372.
23. Piccinini, M.; Mostert, M.; Croce, S.; Baldovino, S.; Papotti, M.; Rinaudo, M. T. Interferon-gamma-inducible subunits are incorporated in human brain 20S proteasome. J. Neuroimmunol., 2003, 135, 135-140.
24. Stohwasser, R.; Giesebrecht, J.; Kraft, R.; Muller, E. C.; Hausler, K. G.; Kettenmann, H.; Hanisch, U. K.; Kloetzel, P. M. Biochemical analysis of proteasomes from mouse microglia: induction of immunoproteasomes by interferon-gamma and lipopolysaccharide. Glia, 2000, 29, 355-365.
25. Rivett, A. J.; Bose, S.; Brooks, P.; Broadfoot, K. I. Regulation of proteasome complexes by gamma-interferon and phosphorylation. Biochimie, 2001, 83, 363-366.
26. Heink, S.; Ludwig, D.; Kloetzel, P. M.; Kruger, E. IFN-gammainduced immune adaptation of the proteasome system is an accelerated and transient response. Proc. Natl. Acad. Sci. USA, 2005, 102, 9241-9246.
27. Khan, S.; van den Broek, M.; Schwarz, K.; de Giuli, R.; Diener, P. A.; Groettrup, M. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J. Immunol., 2001, 167, 6859-6868.
28. Tanaka, K.; Kasahara, M. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gammainducible proteasome activator PA28. Immunol. Rev., 1998, 163, 161-176.
29. Murata, S.; Udono, H.; Tanahashi, N.; Hamada, N.; Watanabe, K.; Adachi, K.; Yamano, T.; Yui, K.; Kobayashi, N.; Kasahara, M.; Tanaka, K.; Chiba, T. Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. Embo J., 2001, 20, 5898-5907.
30. Jung, T.; Catalgol, B.; Grune, T. The proteasomal system. Mol. Aspects Med., 2009, 30, 191-296.
31. Hirano, Y.; Hendil, K. B.; Yashiroda, H.; Iemura, S.; Nagane, R.; Hioki, Y.; Natsume, T.; Tanaka, K.; Murata, S. A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes. Nature, 2005, 437, 1381-1385.
32. Groettrup, M.; Standera, S.; Stohwasser, R.; Kloetzel, P. M. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc. Natl. Acad. Sci. USA, 1997, 94, 8970-8975.
33. Kingsbury, D. J.; Griffin, T. A.; Colbert, R. A. Novel propeptide function in 20 S proteasome assembly influences beta subunit composition. J. Biol. Chem., 2000, 275, 24156-24162.
34. Griffin, T. A.; Nandi, D.; Cruz, M.; Fehling, H. J.; Kaer, L. V.; Monaco, J. J.; Colbert, R. A. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J. Exp. Med., 1998, 187, 97-104.
35. Rock, K. L.; Goldberg, A. L. Degradation of cell proteins and the generation of MHC class I- presented peptides. Annu. Rev. Immunol., 1999, 17, 739-779.
36. Ho, Y. K.; Bargagna-Mohan, P.; Mohan, R.; Kim, K. B. LMP2-specific inhibitors: Novel chemical genetic tools for proteasome biology. Chem. Biol., 2007, 14, 419-430.
37. Fruh, K.; Gossen, M.; Wang, K.; Bujard, H.; Peterson, P. A.; Yang, Y. Displacement of housekeeping proteasome subunits by MHCencoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J., 1994, 13, 3236-3244.
38. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev., 2007, 107, 687-717.
39. Van Kaer, L. Accessory proteins that control the assembly of MHC molecules with peptides. Immunol. Res., 2001, 23, 205-214.
40. Fehling, H. J.; Swat, W.; Laplace, C.; Kuhn, R.; Rajewsky, K.; Muller, U.; von Boehmer, H. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science, 1994, 265, 1234-1237.
41. Sibille, C.; Gould, K. G.; Willard-Gallo, K.; Thomson, S.; Rivett, A. J.; Powis, S.; Butcher, G. W.; De Baetselier, P. LMP2+proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes. Curr. Biol., 1995, 5, 923-930.
42. Basler, M.; Moebius, J.; Elenich, L.; Groettrup, M.; Monaco, J. J. An altered T cell repertoire in MECL-1-deficient mice. J. Immunol., 2006, 176, 6665-6672.
43. Stohwasser, R.; Kuckelkorn, U.; Kraft, R.; Kostka, S.; Kloetzel, P. M. 20S proteasome from LMP7 knock out mice reveals altered proteolytic activities and cleavage site preferences. FEBS Lett., 1996, 383, 109-113.
44. Chen, W.; Norbury, C. C.; Cho, Y.; Yewdell, J. W.; Bennink, J. R. Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J. Exp. Med., 2001, 193, 1319-1326.
45. Yewdell, J. W. Immunoproteasomes: regulating the regulator. Proc. Natl. Acad. Sci. USA, 2005, 102, 9089-9090.
46. Caudill, C. M.; Jayarapu, K.; Elenich, L.; Monaco, J. J.; Colbert, R. A.; Griffin, T. A. T cells lacking immunoproteasome subunits MECL-1 and LMP7 hyperproliferate in response to polyclonal mitogens. J. Immunol., 2006, 176, 4075-4082.
47. Arnold, D.; Driscoll, J.; Androlewicz, M.; Hughes, E.; Cresswell, P.; Spies, T. Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules. Nature, 1992, 360, 171-174.
48. Yewdell, J.; Lapham, C.; Bacik, I.; Spies, T.; Bennink, J. MHCencoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J. Immunol., 1994, 152, 1163-1170.
49. Momburg, F.; Ortiz-Navarrete, V.; Neefjes, J.; Goulmy, E.; van de Wal, Y.; Spits, H.; Powis, S. J.; Butcher, G. W.; Howard, J. C.; Walden, P et al. Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature, 1992, 360, 174-177.
50. Louie, J. L.; Kapphahn, R. J.; Ferrington, D. A. Proteasome function and protein oxidation in the aged retina. Exp. Eye Res., 2002, 75, 271-284.
51. Ferrington, D. A.; Hussong, S. A.; Roehrich, H.; Kapphahn, R. J.; Kavanaugh, S. M.; Heuss, N. D.; Gregerson, D. S. Immunoproteasome responds to injury in the retina and brain. J. Neurochem., 2008, 106, 158-169.
52. Ethen, C. M.; Hussong, S. A.; Reilly, C.; Feng, X.; Olsen, T. W.; Ferrington, D. A. Transformation of the proteasome with agerelated macular degeneration. FEBS Lett., 2007, 581, 885-890.
53. Mishto, M.; Santoro, A.; Bellavista, E.; Sessions, R.; Textoris-Taube, K.; Dal Piaz, F.; Carrard, G.; Forti, K.; Salvioli, S.; Friguet, B.; Kloetzel, P. M.; Rivett, A. J.; Franceschi, C. A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biol. Chem., 2006, 387, 417-429.
54. Tu, L.; Moriya, C.; Imai, T.; Ishida, H.; Tetsutani, K.; Duan, X.; Murata, S.; Tanaka, K.; Shimokawa, C.; Hisaeda, H.; Himeno, K. Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection. Eur. J. Immunol., 2009, 39, 3385-3394.
55. Khan, M. T.; Joseph, S. K. Characterization of membraneassociated proteasomes in WB rat liver epithelial cells. Arch. Biochem. Biophys., 2001, 385, 99-107.
56. Wieland, S.; Thimme, R.; Purcell, R. H.; Chisari, F. V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. USA, 2004, 101, 6669-6674.
57. Robek, M. D.; Garcia, M. L.; Boyd, B. S.; Chisari, F. V. Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. J. Virol., 2007, 81, 483-491.
58. Barton, L. F.; Cruz, M.; Rangwala, R.; Deepe, G. S., Jr.; Monaco, J. J. Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection. J. Immunol., 2002, 169, 3046-3052.
59. Shin, E. C.; Seifert, U.; Kato, T.; Rice, C. M.; Feinstone, S. M.; Kloetzel, P. M.; Rehermann, B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J. Clin. Invest., 2006, 116, 3006-3014.
60. Remoli, A. L.; Marsili, G.; Perrotti, E.; Gallerani, E.; Ilari, R.; Nappi, F.; Cafaro, A.; Ensoli, B.; Gavioli, R.; Battistini, A. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem. J.,2006, 396, 371-380.
61. Gavioli, R.; Cellini, S.; Castaldello, A.; Voltan, R.; Gallerani, E.; Gagliardoni, F.; Fortini, C.; Cofano, E. B.; Triulzi, C.; Cafaro, A.; Srivastava, I.; Barnett, S.; Caputo, A.; Ensoli, B. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine, 2008, 26, 727-737.
62. Nguyen, T. P.; Soukup, V. M.; Gelman, B. B. Persistent hijacking of brain proteasomes in HIV-associated dementia. Am. J. Pathol., 2010, 176, 893-902.
63. Krause, S.; Kuckelkorn, U.; Dorner, T.; Burmester, G. R.; Feist, E.; Kloetzel, P. M. Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders. Ann. Rheum. Dis., 2006, 65, 1021-1027.
64. Morawietz, L.; Martinez-Gamboa, L.; Scheffler, S.; Hausdorf, G.; Dankof, A.; Kuckelkorn, U.; Doerner, T.; Egerer, K.; Burmester, G. R.; Faustman, D. L.; Feist, E. Expression of proteasomal immunosubunit β1i Is dysregulated in inflammatory infiltrates of minor salivary glands in sjogren's syndrome. J. Rheumatol., 2009, 36, 2694-2703.
65. Egerer, T.; Martinez-Gamboa, L.; Dankof, A.; Stuhlmuller, B.; Dorner, T.; Krenn, V.; Egerer, K.; Rudolph, P. E.; Burmester, G. R.; Feist, E. Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjogren's syndrome. Arthritis Rheum., 2006, 54, 1501-1508.
66. Visekruna, A.; Joeris, T.; Seidel, D.; Kroesen, A.; Loddenkemper, C.; Zeitz, M.; Kaufmann, S. H.; Schmidt-Ullrich, R.; Steinhoff, U. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J. Clin. Invest., 2006, 116, 3195-3203.
67. Fitzpatrick, L. R.; Small, J. S.; Poritz, L. S.; McKenna, K. J.; Koltun, W. A. Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease. Dis. Colon Rectum, 2007, 50, 337-348.
68. Fitzpatrick, L. R.; Khare, V.; Small, J. S.; Koltun, W. A. Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice. Dig. Dis. Sci., 2006, 51, 1269-1276.
69. Ferrer, I.; Martin, B.; Castano, J. G.; Lucas, J. J.; Moreno, D.; Olive, M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J. Neuropathol. Exp. Neurol., 2004, 63, 484-498.
70. Yang, Z.; Gagarin, D.; St Laurent, G., 3rd; Hammell, N.; Toma, I.; Hu, C. A.; Iwasa, A.; McCaffrey, T. A. Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 1213-1219.
71. Diaz-Hernandez, M.; Hernandez, F.; Martin-Aparicio, E.; Gomez-Ramos, P.; Moran, M. A.; Castano, J. G.; Ferrer, I.; Avila, J.; Lucas, J. J. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci., 2003, 23, 11653-11661.
72. Diaz-Hernandez, M.; Martin-Aparicio, E.; Avila, J.; Hernandez, F.; Lucas, J. J. Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. Neurotox. Res., 2004, 6, 463-468.
73. Mishto, M.; Bellavista, E.; Santoro, A.; Stolzing, A.; Ligorio, C.; Nacmias, B.; Spazzafumo, L.; Chiappelli, M.; Licastro, F.; Sorbi, S.; Pession, A.; Ohm, T.; Grune, T.; Franceschi, C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol. Aging, 2006, 27, 54-66.
74. Puttaparthi, K.; Elliott, J. L. Non-neuronal induction of immunoproteasome subunits in an ALS model: possible mediation by cytokines. Exp. Neurol., 2005, 196, 441-451.
75. Cheroni, C.; Marino, M.; Tortarolo, M.; Veglianese, P.; De Biasi, S.; Fontana, E.; Zuccarello, L. V.; Maynard, C. J.; Dantuma, N. P.; Bendotti, C. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum. Mol. Genet., 2009, 18, 82-96.
76. Puttaparthi, K.; Van Kaer, L.; Elliott, J. L. Assessing the role of immuno-proteasomes in a mouse model of familial ALS. Exp. Neurol., 2007, 206, 53-58.
77. Liu, Q.; Hao, C.; Su, P.; Shi, J. Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand. J. Gastroenterol., 2009, 44, 960-969.
78. Murakami, Y.; Kanda, K.; Yokota, K.; Kanayama, H.; Kagawa, S. Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: a preliminary study. Mol. Urol., 2001, 5, 113-119.
79. Meidenbauer, N.; Zippelius, A.; Pittet, M. J.; Laumer, M.; Vogl, S.; Heymann, J.; Rehli, M.; Seliger, B.; Schwarz, S.; Le Gal, F. A.; Dietrich, P. Y.; Andreesen, R.; Romero, P.; Mackensen, A. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res., 2004, 64, 6319-6326.
80. Ritz, U.; Momburg, F.; Pilch, H.; Huber, C.; Maeurer, M. J.; Seliger, B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int. J. Oncol., 2001, 19, 1211-1220.
81. Meissner, M.; Reichert, T. E.; Kunkel, M.; Gooding, W.; Whiteside, T. L.; Ferrone, S.; Seliger, B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin. Cancer Res., 2005, 11, 2552-2560.
82. Altun, M.; Galardy, P. J.; Shringarpure, R.; Hideshima, T.; LeBlanc, R.; Anderson, K. C.; Ploegh, H. L.; Kessler, B. M. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res., 2005, 65, 7896-7901.
83. Cerruti, F.; Martano, M.; Petterino, C.; Bollo, E.; Morello, E.; Bruno, R.; Buracco, P.; Cascio, P. Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer. Neoplasia, 2007, 9, 960-969.
84. Wehenkel, M.; Hong, J. T.; Kim, K. B. Proteasome modulators: essential chemical genetic tools for understanding human diseases. Mol. Biosyst., 2008, 4, 280-286.
85. Kisselev, A. F.; Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol., 2001, 8, 739-758.
86. Joazeiro, C. A.; Anderson, K. C.; Hunter, T. Proteasome inhibitor drugs on the rise. Cancer Res., 2006, 66, 7840-7842.
87. Demo, S. D.; Kirk, C. J.; Aujay, M. A.; Buchholz, T. J.; Dajee, M.; Ho, M. N.; Jiang, J.; Laidig, G. J.; Lewis, E. R.; Parlati, F.; Shenk, K. D.; Smyth, M. S.; Sun, C. M.; Vallone, M. K.; Woo, T. M.; Molineaux, C. J.; Bennett, M. K. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res., 2007, 67, 6383-6391.
88. Chauhan, D.; Hideshima, T.; Anderson, K. C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer, 2006, 95, 961-965.
89. Dreicer, R.; Petrylak, D.; Agus, D.; Webb, I.; Roth, B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin. Cancer Res., 2007, 13, 1208-1215.
90. Ikezoe, T.; Yang, Y.; Saito, T.; Koeffler, H. P.; Taguchi, H. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci., 2004, 95, 271-275.
91. Zhou, H. J.; Aujay, M. A.; Bennett, M. K.; Dajee, M.; Demo, S. D.; Fang, Y.; Ho, M. N.; Jiang, J.; Kirk, C. J.; Laidig, G. J.; Lewis, E. R.; Lu, Y.; Muchamuel, T.; Parlati, F.; Ring, E.; Shenk, K. D.; Shields, J.; Shwonek, P. J.; Stanton, T.; Sun, C. M.; Sylvain, C.; Woo, T. M.; Yang, J. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem., 2009, 52(9),3028-3038.
92. Bennett, M. K.; Kirk, C. J. Development of proteasome inhibitors in oncology and autoimmune diseases. Curr. Opin. Drug Discov. Devel., 2008, 11, 616-625.
93. Groll, M.; Kim, K. B.; Kairies, N.; Huber, R.; Crews, C. M. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α',β'-epoxyketone proteasome inhibitors. J. Am. Chem. Soc., 2000, 122, 1237-1238.
94. Kim, K. B.; Ho, Y. K. Epoxyketone-based immunoproteasome inhibitors. U. S. Patent7,642,369, January 5, 2010.